<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathogenesis and pathophysiology of Raynaud phenomenon
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathogenesis and pathophysiology of Raynaud phenomenon
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathogenesis and pathophysiology of Raynaud phenomenon
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fredrick M Wigley, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John S Axford, DSc, MD, FRCP, FRCPCH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark A Creager, MD, FAHA, FACC, MSVM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or emotional stress. The phenomenon is manifested clinically by sharply demarcated color changes of the skin of the digits. Abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses is thought to underlie the primary form of this disorder [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
         RP is considered primary if these symptoms occur alone without evidence of any associated disorder. By comparison, secondary disease refers to the presence of RP in association with a related illness, such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
        </p>
        <p>
         The pathogenesis of RP will be reviewed here. The definition, clinical manifestations, diagnosis, and treatment of the disorder are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">
          "Clinical manifestations and diagnosis of Raynaud phenomenon"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7540.html" rel="external">
          "Treatment of Raynaud phenomenon: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">
          "Treatment of Raynaud phenomenon: Refractory or progressive ischemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          BACKGROUND
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maurice Raynaud stated in 1862 that "local asphyxia of the extremities" was a result of "increased irritability of the central parts of the cord presiding over the vascular innervation" [
         <a href="#rid5">
          5
         </a>
         ]. He wrote, "…I hope to prove that this kind of gangrene has its cause in a vice of innervation of the capillary vessels." In 1930, after observing that even when reflex vasodilation is produced by warming the body, vasospasm could still be induced by putting the hands in cold water, and conversely, that vasospasm could not be produced by body cooling if the hands were kept warm, Sir Thomas Lewis concluded that Raynaud phenomenon (RP) was due to a "local fault" rather than a defect in the central nervous system [
         <a href="#rid6">
          6
         </a>
         ]. A local defect(s) is hypothesized to be responsible for RP. However, the exact abnormality may vary depending upon the underlying cause [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H577098068">
         <span class="h1">
          THERMOREGULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a thermoneutral environment, the level of the body's heat production equals heat loss, and the body's core temperature remains constant. Minor changes in the environmental temperature are handled by changes in skin blood flow [
         <a href="#rid8">
          8
         </a>
         ]. In warm or hot temperatures, vasodilation of cutaneous vessels increases blood flow to the skin, resulting in loss of heat by convection. Sweating also reduces body temperature [
         <a href="#rid8">
          8
         </a>
         ]. One physiologic response to cold temperature is the lowering of blood flow to the skin, thereby reducing the loss of body heat and preserving normal core temperature [
         <a href="#rid9">
          9
         </a>
         ]. Blood flow to the skin is regulated by a complex interactive system involving neural signals, circulating hormones, and mediators released from both circulating cells and blood vessels. Heat loss is reduced via vasoconstriction of the cutaneous arterioles and arteriovenous anastomoses (AVAs) that shunt blood from superficial to deep [
         <a href="#rid10">
          10
         </a>
         ]. During severe cold exposure, heat is also generated by thermogenesis via shivering and by subcutaneous brown adipose tissue [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3350204299">
         <span class="h2">
          Cutaneous arteriovenous shunts
         </span>
         <span class="headingEndMark">
          —
         </span>
         The function of the microcirculation (defined as blood vessels with a diameter &lt;220 to 150 micrometers; composed of arterioles, venules, and capillaries) is to provide nutrition to tissue, remove waste products, and regulate regional blood flow. Arterioles have vasomotor capacity to alter regional blood flow to tissues. The organization of the microcirculation and the control of tissue blood flow varies among different tissues [
         <a href="#rid12">
          12
         </a>
         ]. The cutaneous microcirculation has arterioles and venules that form two plexuses in the dermis, a superficial one in the upper papillary dermis and a lower deep plexus that is located in the dermal-subcutaneous junction [
         <a href="#rid13">
          13
         </a>
         ]. While the plexuses interconnect, they have distinct physiologic functions. The superficial plexus, from which cutaneous capillary loops emerge, runs horizontally, providing nutritional blood flow to the tissue. Numerous AVAs, which are low-resistance conduits that connect the superficial to the deep plexus  (
         <a class="graphic graphic_figure graphicRef140001" href="/z/d/graphic/140001.html" rel="external">
          figure 1
         </a>
         ), are present and concentrated in nonhairy glabrous skin of the fingers and toes, palmar surface of the hands and feet, ears, nose and also in some nonglabrous skin sites.
        </p>
        <p>
         These AVAs bypass the nutritional capillaries and do not directly contribute to the nutritional blood flow that occurs in the cutaneous capillaries. These
         <a class="drug drug_general" data-topicid="8625" href="/z/d/drug information/8625.html" rel="external">
          AVA
         </a>
         structures act as the major thermoregulatory vessels in the skin. The AVAs are richly innervated by the sympathetic adrenergic system, and when stimulated, the AVAs vasoconstrict and shunt blood to the deep plexus leading to heat conservation. Upon whole-body cold exposure, the shunting of blood from the superficial arterioles to the venules in the deep plexus occurs at high flow rates. This vasoconstrictor reflex has a greater impact on blood flow through the AVA than nutritional blood flow [
         <a href="#rid14">
          14
         </a>
         ]. While nonglabrous skin contains only a few AVAs, vasodilation and constriction in the superficial arterioles still occurs, providing an additional role in regulating body temperature. The larger digital arteries (fingers, toes) will also react to increased sympathetic tone.
        </p>
        <p>
         Cutaneous vasoconstriction decreases skin blood flow during cold conditions but maintains nutritional flow via compensatory vasodilation and continued flow in digital arteries, arterioles, and capillaries that maintain tissue perfusion through the non-AVA flow. Even with moderate cold exposure, nutritional blood flow is preserved despite a total reduction in finger flow [
         <a href="#rid14">
          14
         </a>
         ]. Thus, tissue injury does not occur. However, in response to extreme cold exposure, prolonged periods of vasoconstriction in both AVAs and the nutritional capillary can occur [
         <a href="#rid15">
          15
         </a>
         ]. This may lead to tissue injury due to tissue ischemia-reperfusion injury (eg, frostbite). Tissue ischemia with reperfusion injury can also occur if there is microvascular or macrovascular dysfunction or a disease state leading to structural damage of vessels (eg, vasculitis or systemic sclerosis [SSc]). (See
         <a class="local">
          'Secondary Raynaud phenomenon'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2638677330">
         <span class="h2">
          Afferent and efferent pathways
         </span>
         <span class="headingEndMark">
          —
         </span>
         Temperature perception is a critical function of the somatosensory system that protects us from extreme thermal conditions [
         <a href="#rid16">
          16
         </a>
         ]. The preoptical/anterior hypothalamus in the brain is known to act as a "thermostat," receiving information from peripheral signals and coordinating efferent responses [
         <a href="#rid10">
          10,17
         </a>
         ]. The core body temperature and skin surface temperature are thus integrated by peripherally located thermosensitive neurons sending signals to the central nervous system, which then regulates systemic responses.
        </p>
        <p>
         Cutaneous nerves respond to changes in temperature (cold, heat). Afferent pathways are triggered by topical cooling of the skin or general environmental cold temperatures. Local skin cooling triggers both immediate vasoconstriction and subsequent neural signals to the central nervous system. Afferent nerve fibers of the somatosensory system detect environmental stimuli via receptors located on these nerves and on other tissues including blood vessels. The primary afferent neurons convert thermal stimuli into action potentials that relay sensory information to the spinal cord and brain. Cold temperatures activate both A-delta and unmyelinated C fibers [
         <a href="#rid18">
          18
         </a>
         ]. The transient receptor potential ion channel (TRPM8) is the receptor  (
         <a class="graphic graphic_figure graphicRef140414" href="/z/d/graphic/140414.html" rel="external">
          figure 2
         </a>
         ) responsible for detection of various degrees of cold temperature [
         <a href="#rid19">
          19
         </a>
         ]. Activation of the cold receptor TRPM8 in animal models leads to cold avoidance behavior, skin vasoconstriction, and brown fat thermogenesis, all occurring to maintain normal core temperature [
         <a href="#rid20">
          20
         </a>
         ]. While TRPM8 neurons are a molecularly diverse population, a direct association with a defect or unique subtype in these receptors causing Raynaud phenomenon (RP) has not been shown. (See
         <a class="local">
          'Primary Raynaud phenomenon'
         </a>
         below.)
        </p>
        <p>
         The efferent sympathetic mediators regulated by the central nervous system are released from vasoconstrictor and vasodilator nerves that regulate regional blood flow in the skin via the AVAs and small cutaneous arterioles. Blood vessels in the skin are dually innervated by sympathetic noradrenergic nerves that mediate vasoconstriction and sympathetic cholinergic nerves that mediate vasodilation [
         <a href="#rid9">
          9
         </a>
         ]. An increase in blood flow dissipates heat, while a decrease in cutaneous blood flow preserves body heat. Norepinephrine (ie, noradrenaline) is the primary neurotransmitter mediating vasoconstriction via alpha-adrenergic receptors on cutaneous thermoregulatory blood vessels. Under normal conditions, local cooling of the skin leads to a rapid vasoconstriction followed by transient vasodilation and then prolonged vasoconstriction [
         <a href="#rid10">
          10
         </a>
         ]. While the vasodilation is poorly understood, it is thought to counteract the potential tissue damaging effect of prolonged vasoconstriction.
        </p>
        <p class="headingAnchor" id="H2006772390">
         <span class="h3">
          Alpha-2-adrenergic receptors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cold activates vasoconstriction by selectively amplifying vascular smooth muscle contraction to the efferent sympathetic neurotransmitter, norepinephrine (ie, noradrenaline) [
         <a href="#rid21">
          21
         </a>
         ]. AVAs have a particularly dense sympathetic innervation and are thus activated to constrict and reduce skin blood flow following sympathetic output of norepinephrine from either central or peripheral stimuli. The vasoconstriction depends on local activation of adrenergic nerves and the number and affinity of the postsynaptic alpha-2 receptors on cutaneous vessels [
         <a href="#rid22">
          22
         </a>
         ]. Alpha-1 and alpha-2 adrenoceptors are present on the vascular smooth muscle of arteries of human extremities, but alpha-2 adrenoceptors are more prominent on distal arteries. The role of the adrenergic receptors in thermoregulation was demonstrated following the administration of "selective" alpha-1- and alpha-2-adrenergic agonists to human volunteers, which caused a marked reduction in skin or finger blood flow [
         <a href="#rid23">
          23,24
         </a>
         ]. Using an antagonist during local digital cooling alpha-2 blockade was more effective than alpha-1 blockade, suggesting that alpha-2 adrenoreceptors are the dominant receptor involved in thermoregulation [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Local cooling enhances alpha-2 receptor-mediated vasoconstriction, particularly through the alpha-2C subtype [
         <a href="#rid25">
          25
         </a>
         ]. Different subtypes of alpha-2 receptors (alpha 2A, 2B, and 2C) display differing sensitivity to cold using in vitro studies of vessels from both a mouse model and cutaneous human vessels [
         <a href="#rid26">
          26,27
         </a>
         ]. Experiments using an isolated murine tail artery revealed that the alpha 2C subtype is responsible for the thermoregulatory function of the alpha-2 receptors [
         <a href="#rid26">
          26
         </a>
         ]. This suggests that an altered pattern of expression of these alpha-2 subtypes could modify alpha-2 receptor sensitivity during cold exposure but not at normal temperatures [
         <a href="#rid28">
          28
         </a>
         ]. Alpha 2C adrenoreceptors play a prominent role in vasoconstriction of cutaneous arteries after moderate cooling [
         <a href="#rid27">
          27
         </a>
         ]. In a 37°C (98.6°F) in vitro assay using a mouse tail artery, alpha 2C adrenoreceptors are noted to be "silently" stored within the Golgi apparatus. They translocate to the cell surface after cold exposure and contribute to the adrenergic constrictive response. Cooling induces activation of the Rho/Rho kinase signaling pathway, and this prompts translocation of alpha 2C adrenoreceptors from the Golgi complex to the plasma membrane together with augmented sensitivity to Ca++ of contractile proteins [
         <a href="#rid29">
          29
         </a>
         ]. In vitro studies in a murine model provide evidence that the initial trigger for Rho/Rho kinase signaling is proceeded by a rapid increase of reactive oxygen species (ROS) in smooth muscle cells following cold exposure (28°C) [
         <a href="#rid30">
          30
         </a>
         ]. This is a relevant observation since Raynaud vasospastic attacks may initiate a cycle of ischemia and reperfusion with further production of ROS and subsequent activation of the Rho/Rho kinase pathway thus provoking repeated episodes of vasospasm. (See
         <a class="local">
          'Primary Raynaud phenomenon'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2741904715">
         <span class="h3">
          Endothelial mediators
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although vascular smooth muscle can respond directly to circulating hormones or environmental stimuli, important physiologic control of smooth muscle activity is indirectly mediated by endothelial cells. This is important in the regulation of vascular reactivity of both microvascular and larger vessels like digital arteries. Endothelium-derived nitric oxide (NO) contributes to this protective action by inhibiting vascular smooth muscle contraction, proliferation, and migration [
         <a href="#rid31">
          31,32
         </a>
         ]. NO also inhibits platelet aggregation, stimulates platelet disaggregation, and inhibits the adhesion of platelets, lymphocytes, and neutrophils to the endothelial surface [
         <a href="#rid33">
          33
         </a>
         ]. Endothelial cells also release prostaglandins, which are vasodilatory (prostacyclin), and endothelin-1, which is a potent vasoconstrictor. Both prostacyclin and endothelin are thought to regulate regional blood flow and maintain normal vascular integrity [
         <a href="#rid34">
          34
         </a>
         ]. It is notable that endothelin-1 is not released during normal vascular response but is released when there is vascular disease such as occurs in secondary forms of RP [
         <a href="#rid35">
          35
         </a>
         ]. Vascular reactivity is also affected by shear stress, vasoactive substances released during platelet activation (thromboxane, serotonin), changes in blood viscosity, and potentially changes in rheologic properties of blood such as altered red blood cell deformability. Function of the fibrinolytic system appears to be normal in primary RP [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Primary Raynaud phenomenon'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3172821460">
         <span class="h2">
          Other thermoregulatory responses
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonadrenergic
         </strong>
         – While the sympathetic nervous system is the major mediator of vasoconstriction in the skin via release of norepinephrine (ie, noradrenaline) during cold exposure and vasodilation via release of acetylcholine during hot temperature exposure [
         <a href="#rid21">
          21
         </a>
         ], nonadrenergic mechanisms also contribute to reflex vasoconstriction. Nerve endings sense the microenvironment and release factors that contribute to the balance between vasodilation and vasoconstriction [
         <a href="#rid37">
          37
         </a>
         ]. The peripheral nervous system releases vasodilating (eg, substance P, vasoactive intestinal peptide, calcitonin gene-related peptide, neurokinin A) and vasoconstricting (eg, somatostatin, neuropeptide Y) neuropeptides. In addition, angiotensin II, a systemic peptide hormone, can mediate vasoconstriction of cutaneous vessels by activation of angiotensin II type 1 receptors [
         <a href="#rid38">
          38
         </a>
         ]. Other studies suggest the cold-induced vasodilation triggers endothelium-derived hyperpolarization and activation of endothelial calcium-activated potassium channels causing vascular smooth muscle relaxation [
         <a href="#rid39">
          39
         </a>
         ]. There is speculation that RP can be caused by a defect in the vasodilation response leading to unopposed vasoconstriction [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hormonal
         </strong>
         – The thermoregulatory actions of sex hormones take place at the thermosensitive neurons and peripheral vasculature. Estrogen receptors have been localized in several of the hypothalamic structures involved in temperature regulation. Thus, estrogen can influence both the central nervous system and the peripheral vasculature, making the net influences of sex hormones on body temperature complex [
         <a href="#rid40">
          40
         </a>
         ]. There is evidence to suggest that norepinephrine (ie, noradrenaline)-mediated vasoconstriction is higher in premenopausal females at their midmenstrual cycle, a stage of a high estrogen level [
         <a href="#rid41">
          41
         </a>
         ]. Yet estrogen has a vasodilatory effect and increases sweating, mediating a decrease in body temperature [
         <a href="#rid40">
          40
         </a>
         ]. Interestingly, in vitro studies demonstrate the alpha-2C receptors on cutaneous vessels are upregulated when vessels are exposed to estrogen [
         <a href="#rid42">
          42
         </a>
         ]. Subsequent studies show that estrogen acts through the Epac/JNK/AP-1 signaling pathway to induce alpha-2C adrenoreceptor expression [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emotional
         </strong>
         – The specific responses of the distal circulation to emotional stress are not well documented. Early studies demonstrated that emotional stress increases responses to cold to the fingers. Neurons in the dorsomedial hypothalamus (DMH) play a key role in physiologic responses to exteroceptive ("emotional") stress in rats, including tachycardia [
         <a href="#rid44">
          44
         </a>
         ]. Tachycardia evoked from the DMH or seen in experimental stress in rats is blocked by microinjection of muscimol, a gamma-aminobutyric acid type A (GABAA) receptor agonist, into the rostral raphe pallidus (rRP), an important thermoregulatory site in the brain stem, where disinhibition elicits sympathetically mediated activation of brown adipose tissue and cutaneous vasoconstriction in the tail.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          PRIMARY RAYNAUD PHENOMENON
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of whole-body cold exposure or local cooling of the skin have defined several potential thermoregulatory pathways (see
         <a class="local">
          'Thermoregulation'
         </a>
         above) that can lead to the exaggerated vasoconstriction seen in Raynaud phenomenon (RP). The cause of primary RP is thought to be a "local defect" of thermoregulation in the involved peripheral circulation. Abnormal expression of vascular adrenergic receptors, dysregulation of endothelium, and defects in both sensory nerves and non-neuronal pathways have all been suggested as causes of primary RP [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Unlike individuals with secondary RP, patients with primary RP may exhibit reduced total digital blood flow via arteriovenous anastomoses (AVAs), but flow is typically preserved in the nutritional capillaries. Thus, patients with primary RP do not develop critical ischemia.
        </p>
        <p class="headingAnchor" id="H2696337831">
         <span class="h2">
          Altered cutaneous shunts
         </span>
         <span class="headingEndMark">
          —
         </span>
         The distribution of the AVAs to the extremities focuses the decrease in blood flow in response to cold to the fingers and toes more than other body areas such as the forearm or trunk. (See
         <a class="local">
          'Cutaneous arteriovenous shunts'
         </a>
         above.)
        </p>
        <p>
         This unique distribution has implicated a defect or abnormal response in the cutaneous
         <a class="drug drug_general" data-topicid="8625" href="/z/d/drug information/8625.html" rel="external">
          AVA
         </a>
         system in patients with RP. Studies show that even in a thermoneutral environment, finger blood flow is lower in patients with RP (primary or secondary) compared with control subjects [
         <a href="#rid45">
          45
         </a>
         ]. Following localized cooling of the fingers, individuals with primary RP demonstrate increased sensitivity to cold and prolonged recovery of finger blood flow on rewarming. An increase in sympathetic tone causes vasospasm in digital arteries as well as in the cutaneous microcirculation. However, studies using general body cooling found that digital blood flow does not fall to zero in patients with primary RP [
         <a href="#rid46">
          46
         </a>
         ]. In control subjects, total and AVA blood flow is reduced following cool exposure, but nutritional capillary flow is maintained [
         <a href="#rid45">
          45
         </a>
         ]. Nutritional blood flow can be reduced in primary RP under some circumstances, but the reduction is less compared with subjects with secondary RP. In the absence of severe cold conditions, critical ischemic events are not seen in patients with primary RP [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="local">
          'Secondary Raynaud phenomenon'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3660096583">
         <span class="h2">
          Altered alpha-adrenergic response
         </span>
         <span class="headingEndMark">
          —
         </span>
         In primary RP, there is compelling evidence that the increased sensitivity to cold temperatures is mediated in part by abnormal alpha-adrenergic responses, particularly mediated by alpha-2 adrenoreceptors. This points to an increased contribution of alpha-2 adrenoceptors to thermoregulation in the AVAs and cutaneous arteries. (See
         <a class="local">
          'Alpha-2-adrenergic receptors'
         </a>
         above.)
        </p>
        <p>
         The abnormal response via alpha-2 receptors may mediate the exaggerated vasoconstriction as seen in RP [
         <a href="#rid47">
          47
         </a>
         ]. In patients with primary RP, the pathogenic importance of alpha-2 receptors is suggested by experiments with selective receptor antagonists [
         <a href="#rid48">
          48-50
         </a>
         ]. As an example, in 1 report of 23 patients, the mean number of fingers with cold-induced vasospastic attacks was markedly reduced with yohimbine (an alpha-2 receptor blocker) compared with
         <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">
          prazosin
         </a>
         (an alpha-1 receptor blocker [0.3 versus 2.3 fingers]) [
         <a href="#rid49">
          49
         </a>
         ]. It is notable that local cooling of the skin by immersing the finger in ice water was reported to cause more dramatic reduction of digital blood flow and
         <a class="drug drug_general" data-topicid="8625" href="/z/d/drug information/8625.html" rel="external">
          AVA
         </a>
         blood in patients with RP than in individuals without RP [
         <a href="#rid28">
          28
         </a>
         ]. However, the analysis of responses to exogenous administration of agonists has not provided a clear answer to the underlying reason for the increased cold sensitivity of alpha-2 receptors in primary RP. In different studies, the responses to "selective" alpha-2-adrenergic agonists were either increased or unchanged in patients with RP when compared with controls, and responses to "selective" alpha-1-adrenergic agonists were either not changed, increased, or decreased in affected patients [
         <a href="#rid49">
          49-51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2532212177">
         <span class="h2">
          Altered nonadrenergic responses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other than increased sensitivity of alpha-2 receptors as discussed above, there may be other nonadrenergic mechanisms responsible for the excessive vasoconstriction seen clinically as an attack of RP. However, it is unlikely that nonadrenergic mechanisms alone contribute to cold-induced vasospasm in primary RP. Among the complex mechanisms that regulate vascular tone, impaired dilator function of the endothelium [
         <a href="#rid52">
          52
         </a>
         ], increased production of endothelin-1 from the endothelium [
         <a href="#rid53">
          53
         </a>
         ], or decreased sensory nerve innervation (calcitonin gene-related peptide [CGRP]-containing nerve fibers) [
         <a href="#rid54">
          54
         </a>
         ] may also be involved.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endothelial defects
         </strong>
         – Cold-induced cutaneous vasoconstriction is normally constrained by simultaneous cold-induced vasodilation (see
         <a class="local">
          'Afferent and efferent pathways'
         </a>
         above); thus, in theory, a defect in the regulation of sympathetic-induced vasodilation could lead to excessive vasoconstriction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A defect in vasodilation is implicated in RP by a study reporting a reduction in the number of CGRP immunoreactive neurons in the skin of patients with RP [
         <a href="#rid54">
          54
         </a>
         ]. Supporting this concept are case series reporting that treatment of migraine headaches with monoclonal antibodies that are CGRP antagonists is associated with the onset or aggravation of RP [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vascular disease is generally associated with a decreased protective role of the endothelium and diminished activity of nitric oxide (NO) [
         <a href="#rid31">
          31
         </a>
         ]. In theory, a decreased activity of NO may then contribute to worsening vasoconstriction. However, studies in primary RP suggest that the endothelial vasodilatory function is preserved [
         <a href="#rid56">
          56
         </a>
         ]. Studies have failed to demonstrate altered activity of endothelin-1 [
         <a href="#rid52">
          52,57
         </a>
         ], reduced response to vasodilators in primary RP [
         <a href="#rid58">
          58
         </a>
         ], or increased activity of 5-hydroxytryptamine [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Modulation of alpha-adrenergic agonists
         </strong>
         – Nonadrenergic mechanisms could act indirectly to selectively modulate the alpha-2-adrenergic response. Increased contractile responses to alpha-2-adrenergic agonists and cooling observed in patients with RP compared with healthy controls is associated with increased protein tyrosine kinase (PTK) activity and tyrosine phosphorylation [
         <a href="#rid44">
          44,45,59
         </a>
         ]. These abnormalities are described in arteries from patients with primary and secondary RP, providing a theoretical unifying explanation for the cold-induced vascular reactivity. Tyrosine kinase signaling is known to play a key role in vascular biology. In vitro studies using arterioles from humans showed increased contractile responses to alpha-2-adrenergic agonists and cooling in patients with RP compared with healthy controls [
         <a href="#rid60">
          60,61
         </a>
         ]. The agonists elicited large increases in tyrosine phosphorylation only in arterial segments from patients with RP at 31°C. Cooling from 37°C to 31°C elicited a large increase in tyrosine phosphorylation in arterioles from RP patients but not those from control subjects. The increases in tyrosine phosphorylation could be prevented by the PTK inhibitor genistein [
         <a href="#rid61">
          61
         </a>
         ]. Although these studies are dated and used nonspecific inhibitors, they provide another possible interesting explanation for abnormal cold-induced vascular reactivity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H554903580">
         <span class="h2">
          Age-related and hormonal influences
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary RP usually has an age of onset between 15 and 30 years, is more common in females compared with males, and may occur in multiple related family members. This suggests an influence of several factors including sex hormones, changes in body fat composition with age that alters thermogenesis, a shift away from adrenergic responses in cutaneous vessels with aging, a blunting of thermal sensitivity with age, metabolic acclimation as we age, and genetic factors [
         <a href="#rid62">
          62
         </a>
         ]. Population surveys report that RP is more common in age-matched females than males, suggesting that estrogen may have a role as a mediator of changes in peripheral vascular tone [
         <a href="#rid63">
          63
         </a>
         ]. Epidemiologic studies also find a positive association between RP and unopposed estrogen use in postmenopausal women [
         <a href="#rid64">
          64
         </a>
         ]. In vitro studies demonstrate that estrogen upregulates the alpha-2C receptors on cutaneous vessels [
         <a href="#rid42">
          42
         </a>
         ]. In experimental studies, estrogen-induced activity of alpha-2C adrenoreceptor was followed by a potentiated cold-induced vasoconstrictive response in mouse tail arteries, providing evidence that estrogen plays a role in the vasospasm of RP [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H928311288">
         <span class="h2">
          Genetic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional insight into the underlying mechanism of primary RP may be derived by studying patients who belong to families in which the disease is clustered [
         <a href="#rid65">
          65-68
         </a>
         ]. Up to 50 percent of patients with primary RP have a first-degree relative who also has RP and cold sensitivity, and RP is more common among monozygotic twins than dizygotic twins [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A genome-wide screen among families tentatively identified five genetic loci (on the X chromosome and chromosomes 6, 7, 9, and 17) that may be linked with the disease [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study assessed the association between RP and single-nucleotide polymorphisms (SNPs) in genes TRPA1, TRPM8, CALCA, CALCB
         <em>
          ,
         </em>
         and NOS1 [
         <a href="#rid72">
          72
         </a>
         ]. TRPA1 and TRPM8 act as neuronal and vascular cold sensor s. CGRP is a vasodilator neuropeptide that exists in two isoforms in humans, alpha-CGRP and beta-CGRP, encoded by the genes CALCA and CALCB, respectively. The authors also identified one polymorphic variant within the NOS1 gene as significantly associated with RP in the general population. The involvement of neuronal nitric oxide synthase (nNOS)-derived NO in mediating the restorative vasodilator responses after cold exposure provided rationale for investigating the gene NOS1 encoding nNOS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another genome-wide association study identified 5147 cases of RP in the United Kingdom Biobank cohort (based on billing codes in medical records) and compared them with 439,294 controls [
         <a href="#rid73">
          73
         </a>
         ]. Two candidate causal genes were associated with an increased risk for RP including
         <em>
          ADRA2A
         </em>
         (rs7090046, odds ratio [OR] per allele 1.26; 95% CI 1.20 to 1.31) and
         <em>
          IRX1
         </em>
         (rs12653958, OR 1.17; 95% CI 1.12 to 1.22). The association remained for primary RP when excluding cases with secondary diseases. The authors postulated that
         <em>
          ADRA2A
         </em>
         may increase expression of alpha 2A adrenoreceptors in arterial tissue, while
         <em>
          IRX1
         </em>
         may alter genes involved in prostaglandin and/or bradykinin sensing and production. However, the potential role of these genes in the pathogenesis of RP requires further study. (See
         <a class="local">
          'Altered alpha-adrenergic response'
         </a>
         above and
         <a class="local">
          'Altered nonadrenergic responses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          SECONDARY RAYNAUD PHENOMENON
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several diseases  (
         <a class="graphic graphic_table graphicRef77253" href="/z/d/graphic/77253.html" rel="external">
          table 1
         </a>
         ) are associated with abnormal vascular reactivity that either cause vasospasm or are associated with Raynaud phenomenon (RP). It is important to note that the term "secondary RP" includes various diseases that cause vascular compromise with vasospasm that are not classic RP. As an example, vasculitis can damage isolated vessels, leading to critical ischemic events with vasospasm that is isolated to the involved vessels without typical RP events. Unlike individuals without RP or patients with primary RP, during laboratory-based cold exposure, patients with secondary RP exhibit not only reduced total digital blood flow via arteriovenous anastomoses (AVAs) but also reduced flow in the nutritional capillaries; thus, they are more likely to develop critical ischemic events.
        </p>
        <p>
         In secondary forms of RP, it is thought that the underlying vascular disease directly disrupts the normal mechanisms responsible for control of vessel reactivity  (
         <a class="graphic graphic_table graphicRef77253" href="/z/d/graphic/77253.html" rel="external">
          table 1
         </a>
         ). Examples of conditions or exposures resulting in secondary forms of RP and their potential mechanisms are described below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic sclerosis
         </strong>
         – Systemic sclerosis (SSc) is an example of the complexity of mechanisms that can cause secondary RP. In SSc, unique changes in the microvascular system develop in association with intimal fibrosis and endothelial dysfunction [
         <a href="#rid74">
          74,75
         </a>
         ]. The endothelial cell damage or dysfunction appears to occur at an early stage and is associated with increased platelet adhesion, decreased storage of von Willebrand factor, and decreased adenosine uptake [
         <a href="#rid36">
          36,76-80
         </a>
         ]. In SSc, endothelial dysfunction has been suggested with decreased nitric oxide (NO) and prostacyclin but enhanced endothelin-1 production. Changes have been demonstrated, including enhanced endothelial cell thymidine labeling, suggesting the presence of endothelial injury and repair [
         <a href="#rid81">
          81
         </a>
         ]. Increased circulating levels of endothelin-1 and reduced activity of NO [
         <a href="#rid82">
          82-85
         </a>
         ] and increased expression of endothelin receptors in microvessels are thought to lead to vasospasm, tissue hypoxia, and injury [
         <a href="#rid52">
          52,84
         </a>
         ]. Increased activity of reactive oxygen species (ROS) that follows ischemic reperfusion injury may occur due to acute and chronic ischemia-reperfusion injury. (See
         <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">
          "Pathogenesis of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Not all increased vascular reactivity can be attributed to problems with endothelial function or fibro-occlusive vascular disorder seen in patients with SSc.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As an example, a selective increase in alpha-2-adrenergic receptor reactivity may occur in the arterioles of sclerodermatous skin in the absence of demonstrable endothelial cell dysfunction [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Studies addressing endothelial function and vasomotor changes in patients with SSc and RP showed that acute and chronic estrogen administration has some positive effect on flow-mediated dilation of the brachial artery [
         <a href="#rid87">
          87,88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic lupus erythematosus
         </strong>
         – While mechanistic studies are lacking in other rheumatic diseases, it is likely that any perturbation of the endothelium will alter vascular reactivity and cause RP. For example, microvascular changes defined by abnormal nailfold changes seen in systemic lupus erythematosus (SLE) are associated with severe RP [
         <a href="#rid89">
          89
         </a>
         ]. A similar association of nailfold capillary changes and RP is reported in inflammatory muscle disease and other connective tissue diseases [
         <a href="#rid90">
          90
         </a>
         ]. These findings demonstrate that direct injury to the nutritional capillaries can complicate RP in these patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vibration exposure and other conditions
         </strong>
         – Another example of secondary RP is vibration exposure (vibration Raynaud syndrome, vibration white finger syndrome, hand-arm vibration syndrome). Direct damage to vessels and neural dysfunction is implicated in vibration-induced RP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For other conditions associated with secondary RP  (
         <a class="graphic graphic_table graphicRef77253" href="/z/d/graphic/77253.html" rel="external">
          table 1
         </a>
         ), the pathophysiologies responsible for microvascular dysfunction leading to RP are poorly characterized, but related mechanisms (eg, inflammation, endothelial dysfunction) may be responsible (eg, thromboangiitis obliterans) [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/3438.html" rel="external">
          "Patient education: Raynaud phenomenon (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H95777458">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Raynaud phenomenon
         </strong>
         – Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or emotional stress. However, the exact pathogenetic mechanisms of RP are incompletely understood but appear to involve several aspects of thermoregulation. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Background'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thermoregulation
         </strong>
         – Temperature perception is a critical function of the somatosensory system that protects us from extreme thermal conditions. Control of blood vessel reactivity is a complex interactive system involving neural signals, circulating hormones, and mediators released from cells and the blood vessel. This process can be disrupted or perturbed at several potential sites. (See
         <a class="local">
          'Thermoregulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The clinical manifestations of RP may be the final expression of altered thermoregulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary Raynaud phenomenon
         </strong>
         – Abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses is thought to underlie the primary form of this disorder. In primary RP, evidence suggests the defect is an increase in alpha-2-adrenergic responses in the digital and cutaneous vessels. (See
         <a class="local">
          'Primary Raynaud phenomenon'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Secondary Raynaud phenomenon
         </strong>
         – In secondary RP, the defect may vary depending upon the underlying insult to the normal physiology of the digital and cutaneous arteries. Many diseases, disorders, drugs, and environmental exposures have been associated with secondary RP  (
         <a class="graphic graphic_table graphicRef77253" href="/z/d/graphic/77253.html" rel="external">
          table 1
         </a>
         ). In secondary forms of RP, it is thought that the underlying vascular disease disrupts the normal mechanisms responsible for control of vessel reactivity. (See
         <a class="local">
          'Secondary Raynaud phenomenon'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 2005; 17:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357:2042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002; 347:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol 2015; 11:146.
          </a>
         </li>
         <li class="breakAll">
          Raynaud, M. Local asphyxia and symmetrical gangrene of the extremities 1862. New researches on the nature and treatment of local asphyxia of the extremities 1874. Translated by Barlow London: New Syndenham Society,1888.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation of the fingers. A variety of Raynaud's disease. Heart 1929; 14:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005; 44:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CJ, Johnson JM. Responses to hyperthermia. Optimizing heat dissipation by convection and evaporation: Neural control of skin blood flow and sweating in humans. Auton Neurosci 2016; 196:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alba BK, Castellani JW, Charkoudian N. Cold-induced cutaneous vasoconstriction in humans: Function, dysfunction and the distinctly counterproductive. Exp Physiol 2019; 104:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 2003; 78:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenzl A, Kiefer FW. Brown adipose tissue and thermogenesis. Horm Mol Biol Clin Investig 2014; 19:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houben AJHM, Martens RJH, Stehouwer CDA. Assessing Microvascular Function in Humans from a Chronic Disease Perspective. J Am Soc Nephrol 2017; 28:3461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braverman IM. The cutaneous microcirculation. J Investig Dermatol Symp Proc 2000; 5:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coffman JD. Total and nutritional blood flow in the finger. Clin Sci 1972; 42:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nat Med 2011; 17:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKemy DD. How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol Pain 2005; 1:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanosue K, Yanase-Fujiwara M, Hosono T. Hypothalamic network for thermoregulatory vasomotor control. Am J Physiol 1994; 267:R283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002; 416:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schepers RJ, Ringkamp M. Thermoreceptors and thermosensitive afferents. Neurosci Biobehav Rev 2010; 34:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida MC, Hew-Butler T, Soriano RN, et al. Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. J Neurosci 2012; 32:2086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan NA, Vanhoutte PM. Effect of cooling on alpha-1 and alpha-2 adrenergic responses in canine saphenous and femoral veins. J Pharmacol Exp Ther 1986; 238:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003; 29:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coffman JD, Cohen RA. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 1988; 18:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekenvall L, Lindblad LE, Norbeck O, Etzell BM. alpha-Adrenoceptors and cold-induced vasoconstriction in human finger skin. Am J Physiol 1988; 255:H1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawasaki N, Iwase S, Mano T. Effect of skin sympathetic response to local or systemic cold exposure on thermoregulatory functions in humans. Auton Neurosci 2001; 87:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chotani MA, Flavahan S, Mitra S, et al. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000; 278:H1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chotani MA, Mitra S, Su BY, et al. Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004; 286:H59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristensen JK, Engelhart M, Nielsen T. Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon. Acta Derm Venereol 1983; 63:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailey SR, Eid AH, Mitra S, et al. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 2004; 94:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailey SR, Mitra S, Flavahan S, Flavahan NA. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2005; 289:H243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan NA, Vanhoutte PM. Endothelial cell signaling and endothelial dysfunction. Am J Hypertens 1995; 8:28S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirchengast M, Münter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999; 221:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rychlik-Golema W, Mastej K, Adamiec R. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases. Int Angiol 2006; 25:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrick AL, Illingworth K, Blann A, et al. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996; 55:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 2005; 31:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang JA, Kolb KE. Angiotensin II type I receptor blockade attenuates reflex cutaneous vasoconstriction in aged but not young skin. Am J Physiol Heart Circ Physiol 2015; 308:H1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan S, Flavahan NA. Cooling-induced dilatation of cutaneous arteries is mediated by increased myoendothelial communication. Am J Physiol Heart Circ Physiol 2020; 319:H123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charkoudian N, Stachenfeld N. Sex hormone effects on autonomic mechanisms of thermoregulation in humans. Auton Neurosci 2016; 196:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan NN, MacAllister RJ, Colhoun HM, et al. Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. J Clin Endocrinol Metab 2001; 86:2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eid AH, Maiti K, Mitra S, et al. Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2007; 293:H1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fardoun MM, Issa K, Maaliki D, et al. Estrogen increases expression of vascular alpha 2C adrenoceptor through the cAMP/Epac/JNK/AP-1 pathway and potentiates cold-induced vasoconstriction. Vascul Pharmacol 2020; 131:106690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimicco JA, Zaretsky DV. The dorsomedial hypothalamus: a new player in thermoregulation. Am J Physiol Regul Integr Comp Physiol 2007; 292:R47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coffman JD, Cohen AS. Total and capillary fingertip blood flow in Raynaud's phenomenon. N Engl J Med 1971; 285:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engelhart M, Kristensen JK. Raynaud's phenomenon: blood supply to fingers during indirect cooling, evaluated by laser Doppler flowmetry. Clin Physiol 1986; 6:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1987; 241:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coffman JD, Cohen RA. Alpha-2-adrenergic and 5-HT2 receptor hypersensitivity in Raynaud's disease. J Vasc Med Biol 1990; 2:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995; 92:1448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman RR, Moten M, Migály P, Mayes M. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthritis Rheum 1993; 36:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindblad LE, Ekenvall L, Etzell BM, Bevegård S. Adrenoceptors in Raynaud's disease. J Cardiovasc Pharmacol 1989; 14:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knock GA, Terenghi G, Bunker CB, et al. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 1993; 101:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990; 336:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunker CB, Terenghi G, Springall DR, et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990; 336:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RW. Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists. Headache 2019; 59:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringqvist A, Jonason T, Leppert J, Ringqvist I. Non-invasive investigation of endothelium-dependent dilatation of the brachial artery in women with primary Raynaud's phenomenon. Clin Sci (Lond) 1998; 94:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottomley W, Goodfield M. A pathogenic role for endothelin in Raynaud's phenomenon? Acta Derm Venereol 1994; 74:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan F, Coffman JD. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 1994; 89:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furspan PB, Chatterjee S, Mayes MD, Freedman RR. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology (Oxford) 2005; 44:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 2004; 50:1578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castellani JW, Young AJ. Human physiological responses to cold exposure: Acute responses and acclimatization to prolonged exposure. Auton Neurosci 2016; 196:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garner R, Kumari R, Lanyon P, et al. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 2015; 5:e006389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998; 129:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Trafford JC, Lafferty K, Potter CE, et al. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988; 2:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman RR, Mayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996; 39:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGregor AJ, Cherkas LJ, Carter L, et al. The genetic contribution to Raynaud's phenomenon: a population-based twin study. Arthritis Rheum 1999; 42:S233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherkas LF, Williams FM, Carter L, et al. Heritability of Raynaud's phenomenon and vascular responsiveness to cold: a study of adult female twins. Arthritis Rheum 2007; 57:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hur YM, Chae JH, Chung KW, et al. Feeling of cold hands and feet is a highly heritable phenotype. Twin Res Hum Genet 2012; 15:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Susol E, MacGregor AJ, Barrett JH, et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000; 43:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munir S, Freidin MB, Brain S, Williams FMK. Association of Raynaud's phenomenon with a polymorphism in the NOS1 gene. PLoS One 2018; 13:e0196279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann S, Yasmeen S, Jacobs BM, et al. ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon. Nat Commun 2023; 14:6156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009; 36:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtiss P, Svigos K, Schwager Z, et al. Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol 2024; 90:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blann AD, Illingworth K, Jayson MI. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993; 20:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freemont AJ, Hoyland J, Fielding P, et al. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 1992; 126:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazandjian S, Fiessinger JN, Camilleri JP, et al. Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. Acta Derm Venereol 1982; 62:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson JD. The endothelium: its role in scleroderma. Ann Rheum Dis 1991; 50 Suppl 4:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleischmajer R, Perlish JS. [3H]Thymidine labeling of dermal endothelial cells in scleroderma. J Invest Dermatol 1977; 69:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford) 2002; 41:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991; 34:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994; 21:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman RR, Girgis R, Mayes MD. Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma. Lancet 1999; 354:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43:1886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lekakis J, Papamichael C, Mavrikakis M, et al. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol 1998; 82:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lekakis J, Mavrikakis M, Papamichael C, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998; 136:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutolo M, Melsens K, Wijnant S, et al. Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal. Autoimmun Rev 2018; 17:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagy Z, Czirják L. Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease. J Eur Acad Dermatol Venereol 2004; 18:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapouri-Moghaddam A, Saeed Modaghegh MH, Rahimi HR, et al. Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review. Iran J Basic Med Sci 2019; 22:215.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7553 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16224254" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Understanding, assessing and treating Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11438158" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12324557" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical practice. Raynaud's Phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25536485" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A vascular mechanistic approach to understanding Raynaud phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25536485" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A vascular mechanistic approach to understanding Raynaud phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation of the fingers. A variety of Raynaud's disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15741200" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pathogenesis of Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26830064" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Responses to hyperthermia. Optimizing heat dissipation by convection and evaporation: Neural control of skin blood flow and sweating in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31045297" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cold-induced cutaneous vasoconstriction in humans: Function, dysfunction and the distinctly counterproductive.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12744548" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Skin blood flow in adult human thermoregulation: how it works, when it does not, and why.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25390014" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Brown adipose tissue and thermogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28904002" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Assessing Microvascular Function in Humans from a Chronic Disease Perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11147672" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The cutaneous microcirculation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5013870" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Total and nutritional blood flow in the finger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22064429" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ischemia and reperfusion--from mechanism to translation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15847696" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8048634" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hypothalamic network for thermoregulatory vasomotor control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11882888" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Identification of a cold receptor reveals a general role for TRP channels in thermosensation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19822171" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Thermoreceptors and thermosensitive afferents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22323721" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3014112" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effect of cooling on alpha-1 and alpha-2 adrenergic responses in canine saphenous and femoral veins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12841295" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The vasculopathy of Raynaud's phenomenon and scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2843379" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2903677" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : alpha-Adrenoceptors and cold-induced vasoconstriction in human finger skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11476289" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of skin sympathetic response to local or systemic cold exposure on thermoregulatory functions in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749700" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12946937" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6191488" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15087420" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15764673" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7646842" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Endothelial cell signaling and endothelial dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2540223" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1852778" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Nitric oxide: physiology, pathophysiology, and pharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10460693" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16763543" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8712862" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15639062" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Estrogens and neuropeptides in Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25770238" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Angiotensin II type I receptor blockade attenuates reflex cutaneous vasoconstriction in aged but not young skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32469638" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cooling-induced dilatation of cutaneous arteries is mediated by increased myoendothelial communication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26674572" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sex hormone effects on autonomic mechanisms of thermoregulation in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11397846" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17644575" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32407896" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Estrogen increases expression of vascular alpha 2C adrenoceptor through the cAMP/Epac/JNK/AP-1 pathway and potentiates cold-induced vasoconstriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16959861" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The dorsomedial hypothalamus: a new player in thermoregulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5090397" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Total and capillary fingertip blood flow in Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2947773" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Raynaud's phenomenon: blood supply to fingers during indirect cooling, evaluated by laser Doppler flowmetry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3033211" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Alpha-2-adrenergic and 5-HT2 receptor hypersensitivity in Raynaud's disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7664425" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8387786" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2481777" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Adrenoceptors in Raynaud's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8331298" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1978025" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1979366" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31310337" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9616257" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Non-invasive investigation of endothelium-dependent dilatation of the brachial artery in women with primary Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7701873" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A pathogenic role for endothelin in Raynaud's phenomenon?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8124805" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10966463" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Protein tyrosine kinase structure and function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15695304" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15146428" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26924539" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Human physiological responses to cold exposure: Acute responses and acclimatization to prolonged exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25776043" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9696729" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3410065" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : An epidemiological survey of Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8048777" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8670329" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Familial aggregation of primary Raynaud's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The genetic contribution to Raynaud's phenomenon: a population-based twin study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17394182" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Heritability of Raynaud's phenomenon and vascular responsiveness to cold: a study of adult female twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22856358" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Feeling of cold hands and feet is a highly heritable phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10902770" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29698501" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Association of Raynaud's phenomenon with a polymorphism in the NOS1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37828025" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19067252" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vascular disease in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35809798" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8230013" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1610706" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6183893" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1750799" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The endothelium: its role in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1517881" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Sequential dermal microvascular and perivascular changes in the development of scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/903666" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : [3H]Thymidine labeling of dermal endothelial cells in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12154200" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Beauty and the beast. The nitric oxide paradox in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1859492" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7525957" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Localization of endothelin-1 and its binding sites in scleroderma skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10475187" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10943881" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9874070" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9812087" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29427827" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678534" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31156780" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
